F9 and hemoglobin measurement: Unlike viral systems, CRISPR/Cas9 editing yields stable and long-lasting expression of factor IX and hence represents a promising therapy for HB as has already been demonstrated in mammalian experimental models [15] and, using MSC cells as the therapeutic target, in mouse models [13] and human MSCs [12].